11:00 AM - 12:00 PM
Track A - Future of Georgia:
Policy Issues Facing the Life Sciences
During this break out session we will hear from state leaders and industry experts on public policy issues facing the life sciences industry. It will be a great opportunity to hear what the state is working on in healthcare, economic development and technology and how the life sciences industry in Georgia plays into those important issues.
Track B - Business Growth:
Realities of IP in the Life Sciences
Successfully commercializing technology in the life sciences requires strong intellectual property (IP) protection, but what does that really mean for you? This panel will explore the realities of developing, acquiring, and capitalizing on strong IP in the life sciences. We will focus on what academic tech transfer offices, entrepreneurs, and small and large companies can do to foster innovation and create an “ecosystem” to successfully commercialize technology in the life sciences. This discussion will provide suggestions about how to strengthen your IP, facilitate communication with other parties in the “ecosystem,” and strategically plan for the future.
Track C - Biopharmaceuticals & Drugs:
The State of Neurodegenerative Disease: Drug Targets & Alternative, Patient-Centric Clinical Endpoint
Despite massive investments in research for diseases like Alzheimer's and Parkinson's, treatment options for patients are largely non-existent. 'Soft' clinical endpoints like Cognitive Impression scores are difficult to demonstrate statistical significance even when underlying biology is being modified. Industry and practicing clinicians share how they are introducing modern imaging and biomarker measurements as 'harder' endpoints to the FDA, along with including diverse patients in earlier trials to better predict large pivotal trials.
Track D - Medical Device & Digital Health:
Putting Data into the Patient’s Hands
Innovations and clinical advancements are enabling more genetic insights than ever before. Keeping up with the level of innovation around precision medicine is no easy feat. More than 74,000 genetic tests and testing products are on the market, with more than 10 new test released each day. Join us for a discussion around how the data is overload our providers and making it difficult to interpret, while also empowering the patient by giving them a new look into their data.